Table 1.
Structure | Designs tested | Expressed* | Soluble* | αβ-protein CD spectrum | Monomeric† | Well-resolved HSQC | Success (%)‡ |
Fd_5S | 6 | 6 | 6 | 0 | 3 | 0 | 0 (0) |
Fd_5A | 12 | 12 | 12 | 6 | 9 | 4 | 4 (33) |
Fd_7S | 10 | 10 | 8 | 6 | 7 | 1 | 1 (10) |
Fd_7A | 11 | 9 | 8 | 6 | 3 | 3 | 2 (18) |
Fd_9A | 12 | 12 | 11 | 11 | 7 | 3 | 3 (25) |
Rsmn2x2_5 | 9 | 9 | 7 | 8 | 6 | 2 | 2 (22) |
Rsmn2x2_6 | 12 | 12 | 12 | 10 | 4 | 4 | 4 (33) |
The second column shows the number of designs experimentally tested for the backbone blueprints (Fig. 4) indicated in the leftmost column. The subsequent columns give the number of designs that satisfy each criterion.
Expression and solubility were assessed by SDS/PAGE and mass spectrometry.
SEC-MALS was used to determine oligomerization state.
The successful designs are defined as those that satisfy all criteria. The details of the results are shown in SI Appendix, Tables S4–S8.